NewEdge Wealth LLC Buys 45,428 Shares of Medpace Holdings, Inc. $MEDP

NewEdge Wealth LLC lifted its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 1,044.6% during the first quarter, Holdings Channel.com reports. The firm owned 49,777 shares of the company’s stock after buying an additional 45,428 shares during the period. NewEdge Wealth LLC’s holdings in Medpace were worth $23,902,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the stock. Allspring Global Investments Holdings LLC raised its position in shares of Medpace by 164.9% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 3,653 shares of the company’s stock worth $2,086,000 after acquiring an additional 2,274 shares during the last quarter. Assenagon Asset Management S.A. bought a new position in Medpace in the fourth quarter valued at about $4,084,000. Cerity Partners LLC increased its position in Medpace by 41.0% in the fourth quarter. Cerity Partners LLC now owns 80,973 shares of the company’s stock worth $45,478,000 after purchasing an additional 23,530 shares during the period. Northwestern Mutual Wealth Management Co. increased its position in Medpace by 24,930.4% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 101,373 shares of the company’s stock worth $56,936,000 after purchasing an additional 100,968 shares during the period. Finally, SG Americas Securities LLC raised its holdings in Medpace by 881.1% during the 4th quarter. SG Americas Securities LLC now owns 60,144 shares of the company’s stock worth $33,780,000 after purchasing an additional 54,014 shares during the last quarter. 77.98% of the stock is owned by institutional investors.

Medpace Trading Down 0.7%

Shares of Medpace stock opened at $528.12 on Thursday. The company has a market capitalization of $15.08 billion, a PE ratio of 33.19, a PEG ratio of 2.66 and a beta of 1.15. Medpace Holdings, Inc. has a 12 month low of $373.00 and a 12 month high of $628.92. The stock’s fifty day simple moving average is $484.63 and its 200 day simple moving average is $493.49.

Medpace (NASDAQ:MEDP) last posted its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, topping the consensus estimate of $3.98 by $0.27. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The firm had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.53 million. During the same period in the previous year, the company posted $3.10 earnings per share. The company’s revenue for the quarter was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Analysts predict that Medpace Holdings, Inc. will post 17.04 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

MEDP has been the topic of a number of research reports. Wall Street Zen downgraded shares of Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Robert W. Baird reiterated a “neutral” rating and set a $547.00 price target (up from $477.00) on shares of Medpace in a research report on Wednesday, July 8th. Mizuho boosted their price target on shares of Medpace from $495.00 to $586.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. Weiss Ratings restated a “hold (c+)” rating on shares of Medpace in a report on Thursday, July 2nd. Finally, Jefferies Financial Group cut shares of Medpace from a “buy” rating to a “hold” rating and raised their price objective for the company from $490.00 to $515.00 in a research note on Tuesday, July 7th. Two research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Medpace currently has an average rating of “Hold” and an average price target of $473.09.

Insider Activity at Medpace

In other news, General Counsel Stephen P. Ewald sold 16,349 shares of the firm’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the sale, the general counsel owned 20,343 shares of the company’s stock, valued at $9,154,350. This trade represents a 44.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 20.50% of the stock is currently owned by corporate insiders.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.